Secondary Logo

Institutional members access full text with Ovid®

Selected proliferation markers correlated with dynamics of growth in colorectal cancer

Luo, Wu-Xiaa,b,*; Chen, Yea,*; Li, Yun-Taoc,*; Tang, Jiea; Ding, Jinga; Du, Yanga; Wu, Qianga; Liu, Ji-Yana

European Journal of Cancer Prevention: May 2019 - Volume 28 - Issue 3 - p 181–187
doi: 10.1097/CEJ.0000000000000448
Research Papers: Gastrointestinal Cancer
Buy
SDC

For treatment of metastatic colorectal cancer, the dynamics of tumor growth is an important factor for treatment decision. However, it is difficult to evaluate the dynamics of tumor growth, especially those of synchronous metastatic diseases. This study aimed to find some indicators related to tumor proliferation to judge the dynamics of tumor progression. The pathological reports and clinical data of 1205 patients with metastatic colorectal cancer were retrospectively reviewed; 75 patients with known relapse time after radical resection were included, and the expression of proliferation-associated proteins was detected by immunohistochemistry. Relapse-free time (RFT) from radical resection to relapse was obtained to analyze the relationship with expression of these factors. Kaplan–Meier univariate analysis showed that the overexpression of cyclin D1 and epidermal growth factor receptor (EGFR) and late pathological stage after surgery indicated shorter RFT. Multivariate analysis showed that EGFR and the stage were independent predictors of RFT. Expression of EGFR and cyclin D1 and the pathological stage were included as combination risk factors for RFT analysis; more risk factors were correlated with shorter RFT. EGFR and cyclin D1 seemed to be indicators of the dynamics of tumor growth, and overexpression of those molecules may suggest rapid growth and poor prognosis.

aDepartment of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University

bDepartment of Medical Oncology, the First People’s Hospital of Chengdu

cDepartment of General Surgery, the Third People’s Hospital of Chengdu, Chengdu, China

*Wu-Xia Luo, Ye Chen, and Yun-Tao Li contributed equally to the writing of this article.

Correspondence to Ji-Yan Liu, MD, PhD, Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, China Tel/fax: +86 288 542 3609; e-mail: liujiyan1972@163.com

Received September 25, 2017

Accepted February 13, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.